Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Medtronic PLC — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.98, while Medtronic PLC trades at $90.61 (market cap $116.07B). The key difference: Medtronic PLC pays a 3.18% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| JEPQ | MDT | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $105.35 |
52-Week Low | $53.77 | $73.75 |
Market Cap | — | $116.07B |
Enterprise Value | — | $134.82B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.00, up 0.54% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates monthly income, with recent dividends of $0.70, $0.64, and $0.56. News highlights focus on retirement income strategies and tax implications of distributions. Institutional interest remains strong, with Bank of America increasing its stake by 8.9% in Q1 2026.
Outlook remains positive for income-focused investors, though the RSI suggests potential overbought conditions. Key risks include tax treatment of distributions and market volatility affecting the options strategy. The fund's $39 billion AUM and active management support its popularity for yield generation in retirement portfolios.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
